TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF

Osteoclast differentiation and activation

2003 • 6,172 citations

Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

1998 • 5,369 citations

Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density

1997 • 5,058 citations

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1998 • 4,184 citations

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

1999 • 3,340 citations

Identification and characterization of a new member of the TNF family that induces apoptosis

1995 • 2,890 citations

Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

1999 • 2,494 citations

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

1997 • 2,257 citations

Safety and antitumor activity of recombinant soluble Apo2 ligand

1999 • 2,215 citations

Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family

1996 • 1,793 citations

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

1999 • 1,621 citations

TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

2000 • 1,330 citations

Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction

2000 • 1,268 citations

Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL

1998 • 1,177 citations

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

2000 • 1,119 citations

TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells

1997 • 1,054 citations

Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells.

1990 • 1,028 citations

Apo2L/TRAIL and its death and decoy receptors

2003 • 851 citations

RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis

1998 • 729 citations

IL-1 and TNF Antagonists Inhibit the Inflammatory Response and Bone Loss in Experimental Periodontitis

1998 • 596 citations

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy

2003 • 552 citations

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

2001 • 525 citations

Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)

2000 • 511 citations

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

2001 • 419 citations

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

2001 • 397 citations

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

2001 • 385 citations

Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applications

2002 • 382 citations

U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells

2002 • 310 citations

The phosphatidylinositol 3-Kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation

2002 • 303 citations

p38 MAPK-Mediated Signals Are Required for Inducing Osteoclast Differentiation But Not for Osteoclast Function

2002 • 278 citations

RANK ligand and osteoprotegerin in myeloma bone disease

2003 • 260 citations

Temperature-sensitive Differential Affinity of TRAIL for Its Receptors

2000 • 244 citations

Human osteoclasts derive from CD14‐positive monocytes

1999 • 215 citations

Arsenic trioxide–induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL

2003 • 210 citations

Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice

2002 • 177 citations

TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells

1999 • 158 citations

TWEAK Mediates Signal Transduction and Differentiation of RAW264.7 Cells in the Absence of Fn14/TweakR

2003 • 140 citations

Characterization of osteoclast precursors in human blood

2000 • 118 citations

Molecular Cross-talk between the TRAIL and Interferon Signaling Pathways

2002 • 102 citations

Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.

2001 • 96 citations

Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–mediated cytotoxicity by selective up-regulation of TRAIL-R1

2001 • 95 citations

Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation

2000 • 82 citations

TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy

2001 • 80 citations

TGF-β1 and IFN-γ Direct Macrophage Activation by TNF-α to Osteoclastic or Cytocidal Phenotype

2000 • 70 citations